Resverlogix Advances RVX-208 IND Program to Parallel Human Microdosing
- Category: Small Molecules
- Published on Wednesday, 21 March 2007 02:00
- Hits: 1836
CALGARY, Canada | Mar 20, 2007 | Resverlogix Corp. ("Resverlogix") (TSX: RVX) is pleased to announce today that favorable results from previously announced toxicology studies have enabled Resverlogix to advance development timing on their RVX-208 Investigational New Drug (IND) program. The official IND enabling studies are now being initiated and the IND is now targeted for submission during the 3rd quarter of 2007. With the advancement of this critical component of the drug development program for RVX-208, the focus will shift toward completion of an Investigational New Drug (IND) application to enable and support our clinical development program. Despite the advancement of this critical component, Resverlogix will continue the previously announced human microdosing program. The microdosing program will take place parallel to the IND program.
"I am very pleased that key toxicology milestones have been met because clinical staff have been so efficient and thorough in their preclinical reviews of RVX-208. The advancement of our IND program will also lead to the advancement of a Phase I program the timing which of will be updated in the 3rd quarter of 2007," stated Donald J. McCaffrey, President and CEO of Resverlogix Corp. "The advancement of these programs are a very important component of our Strategic Alternatives review program with UBS Securities. The Strategic Alternative analysis with UBS Securities is proceeding and we will continue to work closely with UBS Securities under the terms previously announced. We remain hopeful that a transaction will be concluded in 2007." Mr. McCaffrey added further, "With the recent failure of several competing atherosclerosis programs and our continued path of executed milestones the very successful ongoing results at Resverlogix, we are more convinced than ever that our continuing success is due to being focused on the right target, ApoA-l, for atherosclerosis and cardiovascular disease risk reduction. We have and plan on holding our worldwide lead in the Apo-Al research and development."
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the main underlying cause of cardiovascular disease (CVD). The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX: RVX). For further information, please visit our web site at www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
SOURCE: Resverlogix Corp.